Lost password ?
Gulf Pharmaceutical
Weak quarter
- "Julphar missed our estimates in Q1 2023 and increased its revenue by 8.5% to AED454.1m. The net income turned to a loss of AED2.9m. "
Executive summary
Conflicts of Interest
FIND A REPORT
SIMPLE, TO THE POINT IDEA GENERATION
Each company is researched in depth using a structured, robust and transparent process. Valuations are disciplined and dispassionate.
AlphaMena allows you to compare stocks along a wide range of parameters be it by sector, by geography or an array of investment themes.
Our reports include actuarial as well as off balance-sheet data and governance metrics.
Priority is given to idea generation through quick, to the point, answers by means of browsing from one idea to the next.